Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel - PubMed (original) (raw)

. 2013 Nov 13;8(11):e80478.

doi: 10.1371/journal.pone.0080478. eCollection 2013.

Katarzyna Sikora, Matteo Fassan, Anna Maria Rachiglio, Rocco Cappellesso, Davide Antonello, Eliana Amato, Andrea Mafficini, Matilde Lambiase, Claudia Esposito, Emilio Bria, Francesca Simonato, Maria Scardoni, Giona Turri, Marco Chilosi, Giampaolo Tortora, Ambrogio Fassina, Nicola Normanno

Affiliations

Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel

Aldo Scarpa et al. PLoS One. 2013.

Abstract

Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents that are already approved for clinical use or are in clinical trials. Therefore, the number of biomarkers that will be needed to assess is expected to rapidly increase. This calls for the implementation of methods probing the mutational status of multiple genes for inoperable cases, for which limited cytological or bioptic material is available. Cytology specimens from 38 lung adenocarcinomas were subjected to the simultaneous assessment of 504 mutational hotspots of 22 lung cancer-associated genes using 10 nanograms of DNA and Ion Torrent PGM next-generation sequencing. Thirty-six cases were successfully sequenced (95%). In 24/36 cases (67%) at least one mutated gene was observed, including EGFR, KRAS, PIK3CA, BRAF, TP53, PTEN, MET, SMAD4, FGFR3, STK11, MAP2K1. EGFR and KRAS mutations, respectively found in 6/36 (16%) and 10/36 (28%) cases, were mutually exclusive. Nine samples (25%) showed concurrent alterations in different genes. The next-generation sequencing test used is superior to current standard methodologies, as it interrogates multiple genes and requires limited amounts of DNA. Its applicability to routine cytology samples might allow a significant increase in the fraction of lung cancer patients eligible for personalized therapy.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1

Figure 1. Cytological preparations from transthoracic fine needle aspiration of lung nodules and mutations identified using next generation sequencing.

A) Case #34, a cluster of tumor cells with hyperchromatic nuclei and a high N/C ratio (Papanicolau stain, original magnification ×20); B) Case #29, a solid aggregate of tumor cells with dark nuclei, evident nucleoli and scarce, clear cytoplasm (Diff Quick, original magnification ×20); C) Case #18, section of paraffin-embedded cell block showing p53 immunostaining of cancer cells, where the nuclear accumulation of the mutated protein is evident (original magnification ×20). On the right of each sample is the representation of the reads aligned to the reference genome as provided by the Integrative Genomics Viewer (IGV v.2.1, Broad Institute) software .

References

    1. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359: 1367–1380. - PMC - PubMed
    1. Herbst RS, Lippman SM (2007) Molecular signatures of lung cancer–toward personalized therapy. N Engl J Med 356: 76–78. - PubMed
    1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29. - PubMed
    1. Travis WD, World Health Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology. (2004) Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press.
    1. Fassina A, Cappellesso R, Simonato F, Lanza C, Marzari A, et al. (2012) Fine needle aspiration of non-small cell lung cancer: current state and future perspective. Cytopathology 23: 213–219. - PubMed

Publication types

MeSH terms

LinkOut - more resources